BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Monday, 9 December 1996 - 7:28 A.M. EDT
The Phase I trial is designed to assess the safety of the gel in healthy volunteers. Approximately 36 women will be enrolled in the study, which will be conducted at the Institute of Tropical Medicine in Antwerp. Dr. Marie Laga, Head, STD/HIV Research and Intervention Unit, will serve as the Principal Investigator. In November, Procept received approval from the Institute's Ethics Committee to begin the trial.
Earlier this year, Procept signed a collaborative agreement with Britain's Medical Research Council to evaluate PRO 2000 topical microbicide in a parallel Phase I study, which will be conducted at St. Mary's Hospital in London. If merited by the results of the two trials, the Company plans to conduct a Phase II clinical program to assess the gel's safety in a larger population.
Although the World Health Organization estimates that more than 70% of new HIV infections worldwide are acquired through heterosexual intercourse, there is currently no effective female-controlled method for preventing infection. Extensive laboratory studies have shown that the active ingredient in PRO 2000 topical microbicide can block infection by a wide range of HIV strains. It is also active against the viruses that cause herpes infections.
Procept, Inc., headquartered in Cambridge, Massachusetts, is engaged in the discovery and development of small molecule therapeutics for the prevention and treatment of chronic and life-threatening immune system disorders. The Company's research is based upon its understanding of critical cell receptors responsible for modulating immune responses. Procept is developing therapeutics for the treatment of arthritis, diabetes, organ transplant rejection and infectious diseases, including AIDS and tuberculosis. Procept was founded in 1985 and is traded on the Nasdaq National Market System under the symbol PRCT.
CONTACT: Procept, Inc. Stanley C. Erck President and CEO 617/491-1100 or INFOCUS, Inc. Karen M. Goldman (media) 609/683-9055
Copyright (c) 1996/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
961209
BW961210
Copyright © 1996 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .